BMT & Cellular Therapy | Secretary @ASTCT | Co-Chair @ASTCT CoPG | #bmtsm #CARTcell #lymsm | Personal views | Physician not Provider | 🇵🇰 🏏 🇺🇸 🏈https://bsky.app/profile/medihumdani.bsky.socialhttps://bsky.app/profile/medihumdani.bsky.social/post/3lhlyngbdic2j"God created all diseases except GvHD, that we created" Hillard Lazarus Transplanters carry guilt of poor patient outcomes and NRM. The type of cGVHD 👇 reminds me why I vowed NEVER to use tac/mtx again. With ptCY & other data IMO it is no longer acceptable. #GvHD #alloHCT07 Feb 2025 16:14 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lhlyngbdic2jhttps://bsky.app/profile/medihumdani.bsky.social/post/3lgeyputgys2gAnswer: T-LGL clone. Often donor in origin - Associated with neutropenia. - Can be clonal - rule out viral reactivations (EBV, CMV etc) - I often treat (in neutropenics) 60mg pred x 10-14days [no taper] In this patients, post pred the clonal T-LGL diappeared [contains quote post or other embedded content]23 Jan 2025 04:01 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lgeyputgys2ghttps://bsky.app/profile/medihumdani.bsky.social/post/3lgdufdylt22c❓Quiz ⏲️⏲️: 68yr old MDS patient day +167 post ptCY-based matched Allo HCT. No #GvHD - On 0.5mg of tacrolimus - CBC showed WBC of 2.0; platelets 204. ANC 600/uL - On exam no adenopathy - T-cell chimerism fully donor - PB flow shown below Diagnosis & Rx?? #bmtsm Allo 🦪22 Jan 2025 17:11 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lgdufdylt22chttps://bsky.app/profile/medihumdani.bsky.social/post/3lfpfnnyzyc2ePeople wonder why physicians #burnout Evidence below: Plus do you are expected to do more: - research - administration - teaching - nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)14 Jan 2025 13:54 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lfpfnnyzyc2ehttps://bsky.app/profile/medihumdani.bsky.social/post/3lfiuq74nrc2mCurrent status of ADCs in #lymphoma #DLBCL. Loved developing this invited piece with two lymphoma rising stars @gulrayzahmed & @Taha_CancerDoc @MCWCancerCenter #lymsm https://www.tandfonline.com/doi/full/10.1080/14712598.2025.245352411 Jan 2025 23:35 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lfiuq74nrc2mhttps://bsky.app/profile/medihumdani.bsky.social/post/3lfapylgros2jOur @BMTCTN 1506 deep drive on FLT3 MRD and #alloHCT #AML @BloodJournal -15% have micro-clones = worse RFS -MRD+ relapse with WT or with clones persisting (can monitoring in tailor duration?) -if u eradicate MRD, u r fine -Some micro-clones survive and strike if gilt stops08 Jan 2025 17:49 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lfapylgros2jhttps://bsky.app/profile/medihumdani.bsky.social/post/3lez3jq4ags2lOur new @BMTCTN 1703 analysis busts a few myths: - QOL improved with ptCY - 🩸Cystitis not worse - 2yr GRFS superior 42% vs 29%, p=0.001 - ptCY relapse NOT higher @sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT https://ascopubs.org/doi/10.1200/JCO.24.0092105 Jan 2025 16:55 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lez3jq4ags2lhttps://bsky.app/profile/medihumdani.bsky.social/post/3ldzlnrbctc23Playoff clinched @packers #GoPackGo https://media.tenor.com/e7bl4YZEHfIAAAAC/go-packers.gif?hh=286&ww=40024 Dec 2024 04:18 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3ldzlnrbctc23https://bsky.app/profile/medihumdani.bsky.social/post/3ldw52mjtys2dPink ODI for #breastcancer awareness 🇵🇰 vs. 🇿🇦 #GoPakGo @LubnaChaudhary1 🏏22 Dec 2024 19:19 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3ldw52mjtys2dhttps://bsky.app/profile/medihumdani.bsky.social/post/3ldhqeirpsk2gAir pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. Recently saw my city #Lahore (Pakistan) and nearby #NewDehli breaking air pollution records https://ashpublications.org/blood/article/doi/10.1182/blood.2024026399/534404/Air-pollution-is-associated-with-increased-risk-of17 Dec 2024 01:54 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3ldhqeirpsk2ghttps://bsky.app/profile/medihumdani.bsky.social/post/3ld73ddspm22cLove seeing the Nivo-AVD story in older patients grow in Frontline c Hodgkin Lymphoma | Journal of Clinical Oncology https://ascopubs.org/doi/10.1200/JCO-24-01278 congrats @PallawiTorkaMD Need effective tools is frail/unfit/super elderly #lymsm13 Dec 2024 15:17 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3ld73ddspm22chttps://bsky.app/profile/medihumdani.bsky.social/post/3ld3ckva56k2wSafety and Efficacy of Glofitamab for DLBCL in RW. It works, but like nearly all drugs, works less well in the streets #lymsm https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024014903/534578/Safety-and-Efficacy-of-Glofitamab-for-Relapsed12 Dec 2024 03:15 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3ld3ckva56k2whttps://bsky.app/profile/medihumdani.bsky.social/post/3lcyoimxlgs2pImpressive results of Dara vs. W&W in Smoldering #myeloma. Delay in progression; 📉mortality risk, favorable AE profile. ✅ Checks all the 📦📦 (just because HR SMM does not meet MM definition, doesn't mean it is not a PCD) congrats @vincentrk.bsky.social et al. https://www.nejm.org/doi/full/10.1056/NEJMoa240902911 Dec 2024 02:11 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lcyoimxlgs2phttps://bsky.app/profile/medihumdani.bsky.social/post/3lcqdp7sjs225CD19.20 dual CAR in third or later line DLBCL being presented by @niravshahmd #ASH2407 Dec 2024 18:36 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lcqdp7sjs225https://bsky.app/profile/medihumdani.bsky.social/post/3lco2ydm3p22oI can see the convention center #ASH2406 Dec 2024 20:55 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lco2ydm3p22ohttps://bsky.app/profile/medihumdani.bsky.social/post/3lbs5sqh4hc22Much awaited ECOG 4151 results out. IMO definitely ends debate for autoHCT in MCL in MRD negative CR1. #PracticeChaning and congrats to my friend @timfenske in advancing patient care @MCWCancerCenter @ASH_hematology #ASH2025 https://ash.confex.com/ash/2024/webprogram/Paper212973.html25 Nov 2024 18:31 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lbs5sqh4hc22https://bsky.app/profile/medihumdani.bsky.social/post/3lbq7wk5mks2qGo Pack Go @gbpackers.bsky.social https://media.tenor.com/ycQSt4B29gYAAAAC/green-bay-packers-packers.gif?hh=475&ww=49825 Nov 2024 00:04 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lbq7wk5mks2qhttps://bsky.app/profile/medihumdani.bsky.social/post/3lbfpxktha22sUniversity of Bologna, oldest in the world and its iconic Anatomical Theatre20 Nov 2024 19:51 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lbfpxktha22shttps://bsky.app/profile/medihumdani.bsky.social/post/3lbcmelqrik2oSuper interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024012992/525995/A-real-world-comparison-of-commercial-use19 Nov 2024 14:09 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lbcmelqrik2ohttps://bsky.app/profile/medihumdani.bsky.social/post/3lbb6pma2vk2hImpressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm https://ashpublications.org/blood/article/doi/10.1182/blood.2024025454/525779/Long-term-3-year-follow-up-of-mosunetuzumab-in19 Nov 2024 00:32 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lbb6pma2vk2hhttps://bsky.app/profile/medihumdani.bsky.social/post/3lb6h5w3mz22vPackers aka Bear owners https://media.tenor.com/svM2NUXatD4AAAAC/packers-green.gif?hh=449&ww=49817 Nov 2024 22:25 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lb6h5w3mz22vhttps://bsky.app/profile/medihumdani.bsky.social/post/3lb5q26lb3c2vWNDR Chicago17 Nov 2024 15:32 +0000at://did:plc:i74lclocakptmf3pyxv2l46a/app.bsky.feed.post/3lb5q26lb3c2v